1. Home
  2. ZBAO vs ACRV Comparison

ZBAO vs ACRV Comparison

Compare ZBAO & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZBAO
  • ACRV
  • Stock Information
  • Founded
  • ZBAO 2015
  • ACRV 2018
  • Country
  • ZBAO China
  • ACRV United States
  • Employees
  • ZBAO N/A
  • ACRV N/A
  • Industry
  • ZBAO
  • ACRV Medicinal Chemicals and Botanical Products
  • Sector
  • ZBAO
  • ACRV Health Care
  • Exchange
  • ZBAO NYSE
  • ACRV Nasdaq
  • Market Cap
  • ZBAO 29.9M
  • ACRV 40.4M
  • IPO Year
  • ZBAO 2024
  • ACRV 2022
  • Fundamental
  • Price
  • ZBAO $0.92
  • ACRV $1.32
  • Analyst Decision
  • ZBAO
  • ACRV Buy
  • Analyst Count
  • ZBAO 0
  • ACRV 7
  • Target Price
  • ZBAO N/A
  • ACRV $17.60
  • AVG Volume (30 Days)
  • ZBAO 125.2K
  • ACRV 289.6K
  • Earning Date
  • ZBAO 04-15-2025
  • ACRV 08-12-2025
  • Dividend Yield
  • ZBAO N/A
  • ACRV N/A
  • EPS Growth
  • ZBAO N/A
  • ACRV N/A
  • EPS
  • ZBAO 0.09
  • ACRV N/A
  • Revenue
  • ZBAO $33,673,520.00
  • ACRV N/A
  • Revenue This Year
  • ZBAO $65.08
  • ACRV N/A
  • Revenue Next Year
  • ZBAO $34.27
  • ACRV N/A
  • P/E Ratio
  • ZBAO $9.74
  • ACRV N/A
  • Revenue Growth
  • ZBAO 82.66
  • ACRV N/A
  • 52 Week Low
  • ZBAO $0.78
  • ACRV $1.05
  • 52 Week High
  • ZBAO $4.27
  • ACRV $10.16
  • Technical
  • Relative Strength Index (RSI)
  • ZBAO N/A
  • ACRV 48.28
  • Support Level
  • ZBAO N/A
  • ACRV $1.34
  • Resistance Level
  • ZBAO N/A
  • ACRV $1.48
  • Average True Range (ATR)
  • ZBAO 0.00
  • ACRV 0.09
  • MACD
  • ZBAO 0.00
  • ACRV -0.00
  • Stochastic Oscillator
  • ZBAO 0.00
  • ACRV 33.33

About ZBAO ZHIBAO TECHNOLOGY INC

Zhibao Technology Inc is a insurance technology company engaged in providing digital insurance brokerage services in China. 2B2C digital embedded insurance is their business model which is pioneered in China. It provides customized digital insurance solutions for B-side channels (covering a wide range of industries and organizations, including but not limited to Internet platforms, large and medium-sized enterprises, and government agencies, etc.), embedding them into the channel's existing business matrix, and providing the channel with Provide digital insurance brokerage services to C-end customers.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Share on Social Networks: